Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

3.02%

96.5¢ mesoblast limited

MPC-06-ID Phase 3 results countdown, page-199

First 199 Last

Share
Profile

Follow
Praetorian2011

2,261 Posts.

367

26/01/21

23:34

Post #: 50455156
Share

Originally posted by Southoz: ↑

Well Praetorian2011 we are going to have to agree to disagree on this one.

In a traditional analysis you are comparing the mean response on a rating scale between two groups. Lets say pain – on a scale of 1-10 with 10 being worse pain.

So your treatment group scores on average 5 and your control group 8 at follow-up. Depending on your variability and sample size lets say this is a statistically significant result.

But now the question is whether this 3 point improvement is clinically significant. And you would turn to papers that have derived what is considered a minimum clinically important difference for the scale you have used and in this patient population.

In a responder analysis the problem of what to set as the MCID is just pushed one step down the track. What counts as a responder has been determined – the 50% improvement idea.

But what is being tested now is the proportion of responder in each group. What difference in proportions would be considered to be clinically significant – in the sense of would lead to a change in practice.

Any difference can be statistically significant with a large enough sample. And so its not like you can have 10,000 people and think that a 1% improvement is clinically significant.

Dig deep Praetorian2011 – where else can you get your sample size from – all roads eventually lead back to clinical significance; and statistical significance is set from this - not the other way around.

In terms of the question of whether there is a lot of headroom between the 37% response rate in the P2 trial and my estimate of what is required.

Yep – but this is a very unsophisticated way of looking at the question.

The difference between the 37% and control group estimate was not statistically significant – indicating wide confidence intervals. The estimates arose from a post-hoc analysis where the endpoint was created after the trial had completed. There were numerous methodological weaknesses in the P2 trial. The endpoint in the P3 back pain trial was changed midstream. The results are running late. The landscape is one where MSB has failed to produce a convincing P3 efficacy signal for anything after numerous attempts

That is case for the prosecution. It may still be a very good risk / reward play. That’s for everyone to do their own little assessment of.

Expand

only for a primary endpoint which is massively higher than the industry standard MCWTE for CLBP. If they miss this and nail it on a seconday it will still be a winner but I hope they wont based on the P2 data. Again they have gone high based on the P2 data so they didnt need 3000 people.

MSB Price at posting: $2.41 Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

MND

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

SGQ

St George Mining jumps 8% on news it's appointed two niobium executives – from the world's biggest player, CBMM

IIQ

INOVIQ says it has found a way to test blood for Parkinson's Disease – after Alzheimer's success in June

KOB

Koba jumps on uranium rock chips grading over 7% as uranium price revival evidence mounts

There are more pages in this discussion • 75 more messages in this thread...

First 199 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 96.5¢		Change -0.030(3.02%)		Mkt cap ! $1.124B

Open	High	Low	Value	Volume
$1.00	$1.01	96.5¢	$1.110M	1.132M

Buyers (Bids)

No.	Vol.	Price($)
1	19	96.5¢

Sellers (Offers)

Price($)	Vol.	No.
97.0¢	67357	39

View Market Depth

No.	Vol.	Price($)
6	9824	0.965
14	208835	0.960
10	228320	0.955
15	741927	0.950
5	31116	0.945

Price($)	Vol.	No.
0.970	66129	33
0.975	84885	19
0.980	70774	8
0.985	40723	5
0.990	58627	10

Last trade - 12.56pm 20/08/2024 (20 minute delay)

MSB (ASX) Chart

MPC-06-ID Phase 3 results countdown, page-199

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

St George Mining jumps 8% on news it's appointed two niobium executives – from the world's biggest player, CBMM

INOVIQ says it has found a way to test blood for Parkinson's Disease – after Alzheimer's success in June

Koba jumps on uranium rock chips grading over 7% as uranium price revival evidence mounts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MPC-06-ID Phase 3 results countdown, page-199

Top Stories

Monadelphous profits up 16.2% on strong revenue result, and the market likes it

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

St George Mining jumps 8% on news it's appointed two niobium executives – from the world's biggest player, CBMM

INOVIQ says it has found a way to test blood for Parkinson's Disease – after Alzheimer's success in June

Koba jumps on uranium rock chips grading over 7% as uranium price revival evidence mounts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News